Stocks
Immunome Financial Statements (IMNM) |
||||||||||
| Immunomesmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 05.05.2023 | 09.08.2023 | 09.11.2023 | 28.03.2024 | 14.05.2024 | 14.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 2.36 | 4.26 | 3.57 | 3.83 | 1.03 | 12.7 | |||
| Operating Income, bln rub | -4.47 | -5.77 | -4.63 | -94.7 | -132.3 | -237.4 | ||||
| EBITDA, bln rub | ? | -4.47 | -5.62 | -4.63 | -94.4 | -132.0 | -236.7 | |||
| Net profit, bln rub | ? | -4.07 | -5.56 | -4.35 | -92.6 | -129.5 | -232.0 | |||
| OCF, bln rub | ? | 24.2 | -5.67 | -8.61 | -17.5 | -11.2 | -42.9 | |||
| CAPEX, bln rub | ? | 0.106 | 0.340 | 0.036 | 0.349 | 2.16 | 2.89 | |||
| FCF, bln rub | ? | 24.1 | -6.01 | -8.65 | -17.8 | -13.3 | -45.8 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 6.84 | 10.0 | 8.20 | 98.2 | 133.1 | 249.5 | ||||
| Cost of production, bln rub | 0.148 | 0.157 | 0.166 | 0.257 | 0.263 | 0.843 | ||||
| R&D, bln rub | 3.91 | 5.72 | 3.82 | 90.2 | 127.1 | 226.8 | ||||
| Interest expenses, bln rub | 0.201 | 0.000 | 0.000 | 0.201 | 0.000 | 0.201 | ||||
| Assets, bln rub | 48.1 | 41.4 | 93.2 | 148.5 | 319.8 | 319.8 | ||||
| Net Assets, bln rub | ? | 13.9 | 9.34 | 6.08 | 119.9 | 285.6 | 285.6 | |||
| Debt, bln rub | 0.236 | 0.489 | 0.371 | 1.65 | 1.63 | 1.63 | ||||
| Cash, bln rub | 44.4 | 38.4 | 90.6 | 138.1 | 309.7 | 309.7 | ||||
| Net debt, bln rub | -44.2 | -37.9 | -90.3 | -136.5 | -308.1 | -308.1 | ||||
| Ordinary share price, rub | 4.99 | 7.91 | 8.35 | 10.7 | 24.7 | 2.50 | ||||
| Number of ordinary shares, mln | 12.2 | 12.2 | 12.2 | 22.0 | 10.3 | 10.3 | ||||
| Market cap, bln rub | 61 | 96 | 102 | 235 | 254 | 26 | ||||
| EV, bln rub | ? | 17 | 59 | 12 | 98 | -54 | -282 | |||
| Book value, bln rub | 14 | 9 | 6 | 120 | 286 | 286 | ||||
| EPS, rub | ? | -0.33 | -0.46 | -0.36 | -4.22 | -12.6 | -22.5 | |||
| FCF/share, rub | 1.98 | -0.49 | -0.71 | -0.81 | -1.29 | -4.44 | ||||
| BV/share, rub | 1.14 | 0.77 | 0.50 | 5.46 | 27.7 | 27.7 | ||||
| EBITDA margin, % | ? | -189.1% | -131.7% | -130.0% | -2 467% | -12 831% | -1 866% | |||
| Net margin, % | ? | -172.1% | -130.4% | -121.9% | -2 421% | -12 584% | -1 829% | |||
| FCF yield, % | ? | 2.49% | 3.87% | 2.60% | -3.58% | -18.0% | -177.7% | |||
| ROE, % | ? | -215.9% | -284.5% | -368.3% | -88.9% | -81.3% | -81.3% | |||
| ROA, % | ? | -62.2% | -64.1% | -24.0% | -71.8% | -72.6% | -72.6% | |||
| P/E | ? | -2.03 | -3.63 | -4.55 | -2.20 | -1.10 | -0.11 | |||
| P/FCF | 40.2 | 25.8 | 38.4 | -28.0 | -5.56 | -0.56 | ||||
| P/S | ? | 25.7 | 14.6 | 10.00 | 16.8 | 20.1 | 2.03 | |||
| P/BV | ? | 4.39 | 10.3 | 16.8 | 1.96 | 0.89 | 0.09 | |||
| EV/EBITDA | ? | -0.57 | -2.25 | -0.52 | -0.90 | 0.23 | 1.19 | |||
| Debt/EBITDA | 1.51 | 1.46 | 4.06 | 1.25 | 1.30 | 1.30 | ||||
| R&D/CAPEX, % | 3 692% | 1 681% | 10 619% | 25 840% | 5 872% | 7 850% | ||||
| CAPEX/Revenue, % | 4.48% | 7.98% | 1.01% | 9.12% | 210.3% | 22.8% | ||||
| Immunome shareholders | ||||||||||
